Logo image of GERN

GERON CORP (GERN) Stock Fundamental Analysis

USA - NASDAQ:GERN - US3741631036 - Common Stock

1.32 USD
0 (0%)
Last: 9/19/2025, 8:12:41 PM
1.32 USD
0 (0%)
After Hours: 9/19/2025, 8:12:41 PM
Fundamental Rating

3

We assign a fundamental rating of 3 out of 10 to GERN. GERN was compared to 540 industry peers in the Biotechnology industry. GERN scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. GERN is valued quite expensive, but it does show an excellent growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

In the past year GERN has reported negative net income.
GERN had a negative operating cash flow in the past year.
GERN had negative earnings in each of the past 5 years.
GERN had a negative operating cash flow in each of the past 5 years.
GERN Yearly Net Income VS EBIT VS OCF VS FCFGERN Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -50M -100M -150M -200M

1.2 Ratios

Looking at the Return On Assets, with a value of -15.85%, GERN belongs to the top of the industry, outperforming 80.37% of the companies in the same industry.
GERN has a Return On Equity of -33.91%. This is in the better half of the industry: GERN outperforms 75.74% of its industry peers.
Industry RankSector Rank
ROA -15.85%
ROE -33.91%
ROIC N/A
ROA(3y)-50.19%
ROA(5y)-45.98%
ROE(3y)-104.64%
ROE(5y)-88.33%
ROIC(3y)N/A
ROIC(5y)N/A
GERN Yearly ROA, ROE, ROICGERN Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -50 -100 -150

1.3 Margins

GERN has a better Gross Margin (97.79%) than 97.04% of its industry peers.
GERN does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 97.79%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
GERN Yearly Profit, Operating, Gross MarginsGERN Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -20K -40K -60K -80K

More info and screens

4

2. Health

2.1 Basic Checks

GERN does not have a ROIC to compare to the WACC, probably because it is not profitable.
GERN has more shares outstanding than it did 1 year ago.
The number of shares outstanding for GERN has been increased compared to 5 years ago.
Compared to 1 year ago, GERN has an improved debt to assets ratio.
GERN Yearly Shares OutstandingGERN Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M
GERN Yearly Total Debt VS Total AssetsGERN Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M 500M

2.2 Solvency

GERN has an Altman-Z score of -2.06. This is a bad value and indicates that GERN is not financially healthy and even has some risk of bankruptcy.
GERN has a Altman-Z score (-2.06) which is in line with its industry peers.
GERN has a Debt/Equity ratio of 0.46. This is a healthy value indicating a solid balance between debt and equity.
The Debt to Equity ratio of GERN (0.46) is worse than 72.41% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.46
Debt/FCF N/A
Altman-Z -2.06
ROIC/WACCN/A
WACC9.52%
GERN Yearly LT Debt VS Equity VS FCFGERN Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M -100M 200M -200M

2.3 Liquidity

A Current Ratio of 7.87 indicates that GERN has no problem at all paying its short term obligations.
GERN's Current ratio of 7.87 is fine compared to the rest of the industry. GERN outperforms 72.96% of its industry peers.
GERN has a Quick Ratio of 6.79. This indicates that GERN is financially healthy and has no problem in meeting its short term obligations.
GERN's Quick ratio of 6.79 is fine compared to the rest of the industry. GERN outperforms 68.33% of its industry peers.
Industry RankSector Rank
Current Ratio 7.87
Quick Ratio 6.79
GERN Yearly Current Assets VS Current LiabilitesGERN Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M

More info and screens

7

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 63.89% over the past year.
Looking at the last year, GERN shows a very strong growth in Revenue. The Revenue has grown by 11912.20%.
The Revenue has been growing by 178.45% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)63.89%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%80%
Revenue 1Y (TTM)11912.2%
Revenue growth 3Y281.2%
Revenue growth 5Y178.45%
Sales Q2Q%5459.64%

3.2 Future

The Earnings Per Share is expected to grow by 40.11% on average over the next years. This is a very strong growth
The Revenue is expected to grow by 68.70% on average over the next years. This is a very strong growth
EPS Next Y57.92%
EPS Next 2Y37.46%
EPS Next 3Y33%
EPS Next 5Y40.11%
Revenue Next Year179.18%
Revenue Next 2Y109.1%
Revenue Next 3Y83.69%
Revenue Next 5Y68.7%

3.3 Evolution

Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
GERN Yearly Revenue VS EstimatesGERN Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 500M 1B
GERN Yearly EPS VS EstimatesGERN Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 0 0.5 1

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

GERN reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year GERN is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
GERN Price Earnings VS Forward Price EarningsGERN Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20 40 -40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
GERN Per share dataGERN EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.2 -0.2 0.4

4.3 Compensation for Growth

GERN's earnings are expected to grow with 33.00% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y37.46%
EPS Next 3Y33%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for GERN!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

GERON CORP

NASDAQ:GERN (9/19/2025, 8:12:41 PM)

After market: 1.32 0 (0%)

1.32

0 (0%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-06 2025-08-06/bmo
Earnings (Next)11-05 2025-11-05/bmo
Inst Owners81.82%
Inst Owner Change0.75%
Ins Owners0.08%
Ins Owner Change2.79%
Market Cap842.19M
Analysts80
Price Target3.7 (180.3%)
Short Float %13.91%
Short Ratio10.03
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)29.04%
Min EPS beat(2)22.38%
Max EPS beat(2)35.71%
EPS beat(4)4
Avg EPS beat(4)31.14%
Min EPS beat(4)13.34%
Max EPS beat(4)53.15%
EPS beat(8)8
Avg EPS beat(8)22.06%
EPS beat(12)10
Avg EPS beat(12)18.21%
EPS beat(16)13
Avg EPS beat(16)16.05%
Revenue beat(2)1
Avg Revenue beat(2)-8.43%
Min Revenue beat(2)-19.48%
Max Revenue beat(2)2.61%
Revenue beat(4)3
Avg Revenue beat(4)7.74%
Min Revenue beat(4)-19.48%
Max Revenue beat(4)45.76%
Revenue beat(8)6
Avg Revenue beat(8)182.19%
Revenue beat(12)7
Avg Revenue beat(12)127.18%
Revenue beat(16)10
Avg Revenue beat(16)192.72%
PT rev (1m)6.97%
PT rev (3m)-1.69%
EPS NQ rev (1m)-3.71%
EPS NQ rev (3m)-49.06%
EPS NY rev (1m)12.09%
EPS NY rev (3m)12.6%
Revenue NQ rev (1m)0.27%
Revenue NQ rev (3m)-8.45%
Revenue NY rev (1m)6.18%
Revenue NY rev (3m)5.78%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 5.12
P/FCF N/A
P/OCF N/A
P/B 3.25
P/tB 3.25
EV/EBITDA N/A
EPS(TTM)-0.13
EYN/A
EPS(NY)-0.03
Fwd EYN/A
FCF(TTM)-0.28
FCFYN/A
OCF(TTM)-0.28
OCFYN/A
SpS0.26
BVpS0.41
TBVpS0.41
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -15.85%
ROE -33.91%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 97.79%
FCFM N/A
ROA(3y)-50.19%
ROA(5y)-45.98%
ROE(3y)-104.64%
ROE(5y)-88.33%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.3
Health
Industry RankSector Rank
Debt/Equity 0.46
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 0.26%
Cap/Sales 0%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 7.87
Quick Ratio 6.79
Altman-Z -2.06
F-Score4
WACC9.52%
ROIC/WACCN/A
Cap/Depr(3y)94.77%
Cap/Depr(5y)125.95%
Cap/Sales(3y)140.92%
Cap/Sales(5y)119.57%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)63.89%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%80%
EPS Next Y57.92%
EPS Next 2Y37.46%
EPS Next 3Y33%
EPS Next 5Y40.11%
Revenue 1Y (TTM)11912.2%
Revenue growth 3Y281.2%
Revenue growth 5Y178.45%
Sales Q2Q%5459.64%
Revenue Next Year179.18%
Revenue Next 2Y109.1%
Revenue Next 3Y83.69%
Revenue Next 5Y68.7%
EBIT growth 1Y65.95%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year58.75%
EBIT Next 3Y17.69%
EBIT Next 5YN/A
FCF growth 1Y-25.89%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-26.68%
OCF growth 3YN/A
OCF growth 5YN/A